AGM & EGM Statement

25 July 2011

                             Scancell Holdings Plc                             

                       Result of AGM and General Meeting                       

Scancell Holdings plc, (`Scancell' or the `Company') the developer of
therapeutic cancer vaccines, is pleased to announce the following:

Result of Annual General Meeting

All resolutions proposed at the Annual General Meeting held earlier today were
duly passed.

Result of General Meeting

All resolutions proposed at the General Meeting held earlier today were duly
passed. Following the passing of the resolutions the Company can now proceed
with the subdivision of each Existing Ordinary Share of 1p into 10 new Ordinary
Shares of 0.1p each (the "Subdivision") and the placing to raise £1.73 million,
before costs, by means of the issue of 34,575,410 new Ordinary Shares at 5
pence per share (the "Placing") to fund the working capital of the Company.

The Company has made an application to the London Stock Exchange and it is
expected that Admission of the new Ordinary Shares and the Placing Shares will
take place on 26 July 2011.

Following Admission, the Company will have a single class of shares being
Ordinary Shares of 0.1 pence each and there will be 194,093,310 Ordinary Shares
in issue, each carrying one vote per Ordinary Share. The Company does not hold
any Ordinary Shares in treasury. The total number of voting rights in the
Company's Ordinary Shares will be 194,093,310 and this number may be used by
shareholders as the denominator in calculations to determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Services Authority's
Disclosure and Transparency Rules.

Definitions in this announcement are consistent with those set out in the
Circular issued to shareholders of the Company and dated 30 June 2011, a copy
of which is available on the Company's website.

Enquiries:

Scancell Holdings Plc                                   + 44 (0)207 245 1100 
                                                                             
Professor Lindy Durrant/Dr Richard Goodfellow                                
                                                                             
Hansard Communications                                  + 44 (0)207 245 1100 
                                                                             
Adam Reynolds/Guy McDougall                                                  
                                                                             
Zeus Capital - Nominated Adviser                        + 44 (0)161 831 1512 
                                                                             
Ross Andrews/Tom Rowley                                                      
                                                                             
XCAP Securities Plc - Broker                            [phone] 
                                                                             
John Belliss/Parimal Kumar